On the long holiday of the Mid Autumn Festival and National Day, in a building in the Industrial Agglomeration Zone of Fengquan District, Xinxiang City, Henan Province, three teams were particularly busy. They gave up reunions with their families and devoted all their energy to preparing for a new drug that was about to enter clinical trials. A team led by Dr. Ding Qingjie, the chief scientist, is actively coordinating the overall research and development work of clinical plans; Another team, led by Dr. Zhang Haoyi, is busy preparing clinical batches of drugs; At the same time, the chairman of the company, Wang Yuqiao, and others, negotiated cooperation with a group of visiting investment and financing institutions... as much effort as achievements. After 7 years of unremitting research and development, their independently developed Class I innovative drug - the BTK inhibitor TM471-1- has completed clinical application and is about to enter the first phase of clinical trials. This means that after Azvudine, the drug is expected to become the second approved Class 1 innovative drug in Henan Province. The development of a Class I innovative drug has irreplaceable significance if it can be promoted to clinical practice. "Professor Sun Duxin from the School of Pharmacy at the University of Michigan in the United States believes that based on a large amount of experimental data from preclinical studies, the BTK inhibitor TM471-1 fully possesses two characteristics of a good drug: good efficacy and low toxicity. The relevant person in charge of the Henan Provincial Drug Administration said that currently, the research and development of TM471-1 is at the pinnacle of the pyramid internationally. According to third-party authoritative institutions, the main indicators of its preclinical research are superior to similar international products that have already been listed. The research and development unit of BTK inhibitor TM471-1 is Henan Zhi Microbial Medicine Co., Ltd. under the Xinxiang Wang Group. Wang Group is a well-known local private enterprise that has been deeply engaged in fields such as cement, building materials, and real estate for over 20 years. What does a traditional industry rely on to advance to the forefront of technology and invest heavily in a new track? That was June 2015, when Dr. Ding Qingjie, a scientist studying in the United States from Henan Province, was introduced to Henan Normal University as a high-level talent and appointed as a special professor. Dr. Ding Qingjie has completed his undergraduate and master's studies at his alma mater, and has also pursued further studies at Brown University and Georgetown University in the United States. He has long been engaged in the total synthesis research of complex natural compounds in internationally renowned pharmaceutical companies. Dr. Ding Qingjie has 30 years of experience in drug research and development, especially in drug design and synthesis, and has achieved a series of landmark research results and international patents. Henan Normal University is located in the beautiful city of Xinxiang. It is a university jointly built by Henan Province and the Ministry of Education, and a "Double First Class" university established in Henan Province. In 2016, under the promotion of investment promotion by provincial and municipal governments, Dr. Ding Qingjie was invited to visit Wang Group, led by the Fengquan District Government and Henan Normal University. At that time, Wang Yuqiao, the main founder of the Wang Group, was very eager to achieve the transformation and upgrading of traditional industries. In a sincere and in-depth exchange, the two decided to jointly establish Zhimicrobial Medicine and collaborate deeply with the research team of Ding Qingjie from Henan Normal University. Aiming at the international forefront, bravely climbing the technological peak, and focusing on Class I innovative drugs, a team of over 50 people has set off! However, innovation is as important as it is difficult. In the past 7 years, Wang Group and ZhiMicrobial Medicine have overcome the economic downturn